Facets (new session)
Description
Metadata
Settings
owl:sameAs
Inference Rule:
b3s
b3sifp
dbprdf-label
facets
http://dbpedia.org/resource/inference/rules/dbpedia#
http://dbpedia.org/resource/inference/rules/opencyc#
http://dbpedia.org/resource/inference/rules/umbel#
http://dbpedia.org/resource/inference/rules/yago#
http://dbpedia.org/schema/property_rules#
http://www.ontologyportal.org/inference/rules/SUMO#
http://www.ontologyportal.org/inference/rules/WordNet#
http://www.w3.org/2002/07/owl#
ldp
oplweb
skos-trans
virtrdf-label
None
About:
In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect
Goto
Sponge
NotDistinct
Permalink
An Entity of Type :
schema:ScholarlyArticle
, within Data Space :
covidontheweb.inria.fr
associated with source
document(s)
Type:
Academic Article
research paper
schema:ScholarlyArticle
New Facet based on Instances of this Class
Attributes
Values
type
Academic Article
research paper
schema:ScholarlyArticle
isDefinedBy
Covid-on-the-Web dataset
has title
In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect
Creator
Raoult, Didier
Colson, Philippe
Rolain, Jean-Marc
Scola, Bernard
Andreani, Julien
Boxberger, Manon
Colson, J-M
Duflot, Isabelle
Jardot, Priscilla
Le Bideau, Marion
Le Bideau, Andreani
Rolain, Wurtz
Rolland, Clara
Scola B, La
Wurtz, Nathalie
Source
Elsevier; Medline; PMC
abstract
Abstract Human coronaviruses SARS-CoV-2 appeared at the end of 2019 and led to a pandemic with high morbidity and mortality. As there are currently no effective drugs targeting this virus, drug repurposing represents a short-term strategy to treat millions of infected patients at low costs. Hydroxychloroquine showed an antiviral effect in vitro. In vivo it showed efficacy, especially when combined with azithromycin in a preliminary clinical trial. Here we demonstrate that the combination of hydroxychloroquine and azithromycin has a synergistic effect in vitro on SARS-CoV-2 at concentrations compatible with that obtained in human lung.
has issue date
2020-04-25
(
xsd:dateTime
)
bibo:doi
10.1016/j.micpath.2020.104228
bibo:pmid
32344177
has license
els-covid
sha1sum (hex)
aa942370307672dd0c2013494e35b610a8d68411
schema:url
https://doi.org/10.1016/j.micpath.2020.104228
resource representing a document's title
In vitro testing of combined hydroxychloroquine and azithromycin on SARS-CoV-2 shows synergistic effect
has PubMed Central identifier
PMC7182748
has PubMed identifier
32344177
schema:publication
Microb Pathog
resource representing a document's body
covid:aa942370307672dd0c2013494e35b610a8d68411#body_text
is
schema:about
of
named entity 'In vitro'
named entity 'Microbial'
named entity 'testing'
named entity 'HYDROXYCHLOROQUINE'
named entity 'PATHOGENESIS'
named entity 'COMBINED'
named entity 'SARS-COV-2'
named entity 'MICROBIAL'
named entity 'SARS-CoV-2'
named entity 'SARS-CoV-2'
named entity 'hydroxychloroquine'
named entity 'lyses'
named entity 'viruses'
named entity 'clinical study'
named entity 'Human coronaviruses'
named entity 'hydroxychloroquine'
named entity 'H60'
named entity 'azithromycin'
named entity 'cytotoxicity'
named entity 'Kruskal-Wallis test'
named entity 'multiple comparison'
named entity 'potency'
named entity 'positive controls'
named entity 'antiviral effect'
named entity 'hydroxychloroquine'
named entity 'positive control'
named entity 'Teicoplanin'
named entity 'Coronavirus'
named entity 'azithromycin'
named entity 'RNA'
named entity 'intracellular'
named entity 'Chloroquine'
named entity 'epidemic'
named entity 'azithromycin'
named entity 'hydroxychloroquine'
named entity 'hydroxychloroquine'
named entity 'quinine'
named entity 'P-values'
named entity 'SARS-CoV-2'
named entity 'hydroxychloroquine'
named entity 'P-value'
named entity 'SARS-CoV'
named entity 'viral load'
named entity 'SARS-CoV'
named entity 'drug repurposing'
named entity 'hydroxychloroquine'
named entity 'azithromycin'
named entity 'mice models'
named entity 'antibacterial'
named entity 'SARS-CoV-2'
named entity 'hydroxychloroquine'
named entity 'antiviral activity'
named entity '1, 2'
named entity 'Azithromycin'
named entity 'Coronavirus'
named entity 'Zika'
named entity 'synergistic effect'
named entity 'azithromycin'
named entity 'Microbial Pathogenesis'
named entity 'doi'
named entity 'viral replication'
named entity 'SARS-CoV-2'
named entity 'Vero E6'
named entity 'vaccine'
named entity 'azithromycin'
named entity 'hydroxychloroquine'
named entity 'macrolide'
◂◂ First
◂ Prev
Next ▸
Last ▸▸
Page 1 of 2
Go
Faceted Search & Find service v1.13.91 as of Mar 24 2020
Alternative Linked Data Documents:
Sponger
|
ODE
Content Formats:
RDF
ODATA
Microdata
About
OpenLink Virtuoso
version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software